Biosimilar market savings quantification — measuring actual cost reductions achieved through biosimilar adoption for healthcare systems, payers, and patients — provides the policy evidence that justifies biosimilar program investment and informs future biosimilar policy development, with the Biosimilars Market reflecting savings documentation as an important market communication activity.

RAND Corporation biosimilar savings analyses — periodic RAND reports calculating projected US biosimilar savings demonstrating potential savings of $54-160 billion over ten years — have provided the policy benchmark that Congressional biosimilar promotion arguments reference. The RAND savings estimates' assumptions about adoption rates, price discounts, and market penetration timelines have been progressively validated or revised as actual biosimilar market performance provides empirical data.

European national health system biosimilar savings documentation — NHS England, Danish Medicine Agency, and other European health authorities documenting biosimilar savings in their specific healthcare contexts — demonstrate the actual savings achieved through structured biosimilar programs. NHS England's biosimilar savings program documenting hundreds of millions annually from anti-TNF, oncology, and insulin biosimilar adoption provides the real-world savings evidence that policy makers use to design future biosimilar incentive programs.

Patient-level biosimilar savings transparency — the disconnect between substantial payer-level biosimilar savings and minimal patient out-of-pocket benefit where rebate structures benefit payers without passing savings to patients — represents the equity issue that biosimilar savings communication must address. US patients often face similar or higher out-of-pocket costs for biosimilars versus reference biologics because their cost-sharing is based on list price, capturing none of the net price reduction that payers negotiate.

Do you think US healthcare policy should require that biosimilar savings be passed through to patients at the point of sale rather than retained by payers and PBMs?

FAQ

How much have biosimilars saved US healthcare? IQVIA estimates biosimilars saved US healthcare approximately $23 billion in 2021 alone; RAND projects cumulative US savings of $180 billion over ten years if biosimilar adoption continues at current trajectory; adalimumab biosimilar competition is projected to add $40+ billion in additional savings; actual savings depend on adoption rates, price discounts achieved, and whether list-price or net-price savings are measured.

Who benefits from biosimilar savings in the US? In the US, most biosimilar savings accrue to payers (insurance companies, PBMs) through lower net prices after rebates; patients with percentage-based cost-sharing may pay similar or higher amounts on biosimilar versus reference biologic list prices; patients in Medicare Part D benefit from the $35 insulin cap; policy proposals including "sharing" clauses would require a portion of biosimilar savings to reduce patient out-of-pocket costs.

#BiosimilarsMarket #BiosimilarSavings #BiosimilarPolicy #HealthcareCostBiosimilar #BiosimilarAccess #NHSbiosimilarSavings